While the primary analysis of WARSS showed no significant advantage of warfarin compared to aspirin in secondary prevention of noncardioembolic strokes, the subgroup analysis suggested that warfarin was associated with one-third fewer recurrent strokes than aspirin in cryptogenic stroke patients with an embolic appearance, though the result did not reach statistical significance 15 .
1
—
—